Altered growth hormone and prolactin responses to dopaminergic stimulation in huntington's chorea

Tommaso Caraceni, Alberto E. Panerai, Eugenio A. Parati, Daniela Cocchi, Eugenio E. Müller

Research output: Contribution to journalArticlepeer-review


Seven patients affected by Huntington's chorea were given an acute administration of 2-Br-α-ergocryptine (CB 154, Sandoz), a direct agonist at dopamine receptor sites. Seven nonobese hospitalized patients were used as controls. Oral administration of CB 154 (2.5 mg) induced a more prompt and consistent rise in plasma growth hormone (GH) levels in patients than in controls. GH levels rose from baseline values of 0.3 ±0.1 ng/ml to mean peak values of 20.4 ±5.1 ng/ml (120-270 min) in choreic subjects and from baseline values of 1.0 ± 0.4 ng/ml to mean peak values of 5.7 ± 1.6 ng/ml (180-300 min) in control subjects (P < 0.02). Baseline plasma prolactin (PRL) values were significantly higher in choreic than in control subjects (22.1 ± 6.6 ng/ml vs. 8.1 ± 1.4 ng/ml, respectively, P < 0.02); administration of CB 154 induced a more consistent PRL decrease in control than in choreic subjects. Collectively, these results suggest the existence of an abnormal regulation of GH and PRL secretion in Huntington's chorea, probably due to alterations in central dopaminergic neurotransmission.

Original languageEnglish
Pages (from-to)870-875
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Issue number5
Publication statusPublished - 1977

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical


Dive into the research topics of 'Altered growth hormone and prolactin responses to dopaminergic stimulation in huntington's chorea'. Together they form a unique fingerprint.

Cite this